WA-AUTH0
12.1.2022 14:02:05 CET | Business Wire | Press release
Auth0 , a product unit within Okta (NASDAQ: OKTA), today released the findings of its first Public Sector Identity Index , a global research report that provides government technology leaders with insight into the identity maturity of public sector organizations around the world. The report highlights the importance of a centralized identity strategy in putting safe and accessible services into the hands of citizens faster.
Over the past two years, many public sector organizations were prompted by the immediate need to deploy digital infrastructure to maintain continuity of their services amid the COVID-19 pandemic — such as offering citizens license renewals online and virtual education — and are now grappling with the impacts on cybersecurity and user experience. From the Executive Order on ‘Improving the Nation’s Cybersecurity’ in the U.S., to digital identity and Single Sign-On (SSO) initiatives in the UK and Australia, enabling employees, citizens, and other government entities to access all of these applications easily and securely has become a demand around the world.
The 2022 Public Sector Identity Index, conducted by Auth0 and Market Connections , captures the perceptions of 850 IT and line of business decision-makers within national and state/local government organizations across the U.S., UK, and ANZ (Australia and New Zealand) with regard to their Identity and Access Management (IAM) strategy.
The report’s key findings include:
- Only one in five are extremely confident in either the security (17%) or ease of use (19%) of their current authentication solution.
- Username and password is the most frequently used authentication method by citizens (86%), compared to very little usage of biometric or passwordless authentication (16%).
- Four in ten are currently building their own IAM solution in-house (41%), and cite speed to implementation (83%) and using internal staff to manage IAM internally (82%) as two of the biggest pain points in doing so.
- Most governments are looking to expand their digital services in the next two years (75%) and rank protecting citizen’s privacy and data as most important when thinking about citizen services (73%).
Regional analysis shows U.S. respondents rank ensuring citizens’ trust in digital services as an area of high importance (71%), but have less confidence in their organization’s ability to deliver this (56%). Similar discrepancies in importance versus confidence in delivery include speed in adding new services in the UK (66% importance vs. 48% confidence), and improving the user experience in ANZ (72% importance vs. 60% confidence).
Dean Scontras, Vice President of State and Local Government and Education (SLED) at Okta, said: “Digitization is likely to continue in light of Zero Trust mandates and mounting consumer expectations. Public sector organizations greatly benefit from bringing their identity management strategy in line with their digital goals. While there is a strong focus on securing citizen data, the vast majority of applications are still protected by a username and password, despite their well-documented security risks.”
According to Forrester Research, the public sector has a massive influence on the entire economy making up 30% of the global GDP and 33% of the global workforce, and the global research firm predicts that more governments will adopt Zero Trust frameworks to revive public trust in digital services.1
An Identity-First approach puts identity at the center of government digital transformation, while also laying the foundation for a Zero Trust security model. Key to this approach are modern login technologies that replace traditional passwords, and introduce friction only when suspicious behavior is detected. By making the shift to Identity-First, organizations like Larimer County provide easy and seamless access for legitimate users, while decreasing the risk of security and compliance breaches.
Jessica Figueras, a cybercrime and digital identity advisor to governments and Okta consultant, said: “In the face of increasing digitization, skills shortages, and online harms, governments are taking a hard look at the technologies they can bring onboard to help them reach their digital goals. The research suggests that identity is one such technology that can help the public sector do more with less.”
To learn more and download the full report, please visit: 2022 Auth0 Public Sector Identity Index .
Methodology
Auth0 engaged Market Connections to design an online survey of 850 IT and line of business decision-makers within national and state/local governments in the U.S. (200 federal, 200 state & local), UK (100 federal, 100 state & local), and ANZ (Australia and New Zealand) (155 federal/national, 95 state & local), fielded in September-October 2021.
About Auth0
Auth0, a product unit within Okta, takes a modern approach to identity and enables organizations to provide secure access to any application, for any user. The Auth0 Identity Platform is highly customizable, and is as simple as development teams want, and as flexible as they need. Safeguarding billions of login transactions each month, Auth0 delivers convenience, privacy, and security so customers can focus on innovation. For more information, visit https://auth0.com .
About Okta
Okta is the leading independent identity provider. The Okta Identity Cloud enables organizations to securely connect the right people to the right technologies at the right time. With more than 7,000 pre-built integrations to applications and infrastructure providers, Okta provides simple and secure access to people and organizations everywhere, giving them the confidence to reach their full potential. More than 14,000 organizations, including JetBlue, Nordstrom, Siemens, Slack, Takeda, Teach for America, and Twilio, trust Okta to help protect the identities of their workforces and customers.
Disclaimer:
Research reports and related summaries referenced herein are provided for informational purposes only, and consist of the opinions of the organizations publishing such research and should not be construed as statements of fact. Okta and Auth0 make no representations, warranties, or other assurances with respect to such research.
1 Public Sector Predictions 2022, Forrester Research, Inc., November 3, 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
